CrowdStrike Holdings (CRWD) has an average rating of overweight and mean price target of $646.71, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $700.48, Change: $-47.13, Percent Change: -6.30%
Celsius (CELH) is facing an investigation by Texas Attorney General Ken Paxton over the company's marketing practices related to its energy drinks containing high levels of caffeine, the attorney general's office said in a Thursday statement.The office said Celsius and its subsidiary Alani Nutrition market energy drinks using youth-oriented packaging and branding, despite products containing high caffeine levels. It said this raises concerns over whether the company is marketing a potentially harmful product to children and adolescents.Paxton said the office will investigate whether Celsius and Alani misled consumers regarding the safety of their products in violation of the Texas Deceptive Trade Practices Act.Celsius did not immediately respond to a request for comment from.Shares of Celsius were down 4.5% in Thursday afternoon trading.Price: $28.66, Change: $-1.36, Percent Change: -4.52%
Snap (SNAP) has acquired spatial augmented reality firm Illumix, as the parent company of Snapchat looks to boost its AR efforts, Variety reported Thursday.Under the terms of the deal, Snap will use Illumix's technology and platform toward its revamped Specs glasses, and will retain most of Illumix's staff, the report said.Financial details related to the acquisition were not disclosed, according to the report.Snap did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $6.11, Change: $+0.38, Percent Change: +6.63%
Medtronic (MDT) could deliver upside to fiscal 2027 guidance as cardiac ablation, renal denervation, Hugo, Stealth AXiS, and Altaviva momentum support growth, RBC Capital Markets said in a note Wednesday.Medtronic beat fiscal Q4 estimates, delivering 6.6% organic revenue growth and adjusted earnings of $1.55 per share. Cardiac ablation solutions led the beat, with sales up 78% from a year earlier and US growth of 124%, the brokerage said.Management's fiscal 2027 guidance came in below consensus, but several growth drivers are improving at the same time, including renal denervation that analysts described as underappreciated, according to the note.The brokerage said it now models fiscal 2027 adjusted sales growth of 7.1% and adjusted earnings of $5.96 per share.RBC Capital Markets maintained its outperform rating and $118 price target on the stock.Shares of Medtronic were up more than 4% in Thursday trading.Price: $81.58, Change: $+3.63, Percent Change: +4.66%